Autopsy report · NCT00951379

Pioglitazone for Oral Premalignant Lesions

“Due to slow accrual.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 6 months before it started.
• Ran for about 4 years 1 month before it stopped.
• 52 participants enrolled.
• Results were posted on the registry 2 years 1 month after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

National Cancer Institute (NCI)

Sponsor type

US National Institutes of Health

Conditions

Oral Leukoplakia

Interventions

Pioglitazone hydrochloride; placebo; laboratory biomarker analysis

Participants

52

Sites

13

Countries

Canada, Italy, United States

Trials that died the same way

• Staging Procedures to Diagnose Malignant Pleural Mesothelioma
  “due to low/slow accrual” (89% match in meaning)
• Paclitaxel and Carboplatin or Temozolomide in Treating Patients With Stage IV Melanoma
  “Slow accrual.” (82% match in meaning)
• A Study of Olaparib and Durvalumab in Prostate Cancer
  “Due to low accrual” (82% match in meaning)
• Individualized Therapy Based of Tumoral mRNA Levels of ERCC1, RRM1 and BRCA1 in Advanced Non-Small-Cell Lung Cancer
  “Due to poor accrual” (79% match in meaning)
• Cryosurgery and Radiation Therapy in Treating Patients With Painful Bone Metastases
  “Slow Accruals” (78% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.